53658-98-3 Usage
Description
11-DEOXY-16,16-DIMETHYL PROSTAGLANDIN E2, also known as AY 24609, is a stable synthetic analog of PGE2. It acts as an agonist for both EP2 and EP3 receptors and is a potent inhibitor of gastric acid secretion and ulcer formation in rats. It is 900 times more potent than PGF2α in the contraction of human respiratory tract smooth muscle in vitro.
Uses
Used in Pharmaceutical Industry:
11-DEOXY-16,16-DIMETHYL PROSTAGLANDIN E2 is used as a therapeutic agent for the treatment of gastric ulcers and acid-related disorders in rats. It functions as an inhibitor of gastric acid secretion and ulcer formation, making it a potential candidate for the development of anti-ulcer drugs.
Used in Research Applications:
11-DEOXY-16,16-DIMETHYL PROSTAGLANDIN E2 is used as a research tool for studying the effects of EP2 and EP3 receptor agonism on various physiological processes. Its potent activity in the contraction of human respiratory tract smooth muscle in vitro makes it valuable for investigating the role of prostaglandins in respiratory function and related disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 53658-98-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,6,5 and 8 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 53658-98:
(7*5)+(6*3)+(5*6)+(4*5)+(3*8)+(2*9)+(1*8)=153
153 % 10 = 3
So 53658-98-3 is a valid CAS Registry Number.
53658-98-3Relevant articles and documents
Alkyl derivatives of prostanoic acids and preparation thereof
-
, (2008/06/13)
15- And/or 16-alkyl derivatives of 9,15-dioxygenated prost-13-enoic, prosta-4,13-dienoic and prosta-5,13-dienoic acid, lower alkyl esters thereof and homologs thereof, as well as a process for preparing these derivatives are disclosed. The compounds possess hypotensive, antihypertensive, bronchospasmolytic, gastric acid secretion inhibiting, abortifacient, estrus synchronizing and ovulation regulating properties. The compounds also inhibit the aggregation of platelets and promote the disaggregation of aggregated platelets. Methods for their use are also disclosed.